Immune response to dengue virus and prospects for a vaccine

Annual Review of Immunology

Volumn 29, Issue , 2011, Pages 587-619

  Murphy, Brian R ^a   Whitehead, Stephen S ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

antibody dependent enhancement; DENV; DHF DSS; immunization

Indexed keywords

AUTOANTIBODY; CHIMERIC VIRUS VACCINE; CHIMERIVAX; DENGUE VACCINE; DENGUE VIRUS ANTIBODY; FC RECEPTOR; INACTIVATED VIRUS VACCINE; LIVE VACCINE; NONSTRUCTURAL PROTEIN 1; PROTEIN E; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS PROTEIN;

ADAPTIVE IMMUNITY; ARTICLE; CELLULAR IMMUNITY; DENGUE; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; DENGUE VIRUS 4; HUMAN; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; SECONDARY INFECTION; VIRAL GENETICS; VIRION; VIRUS MORPHOLOGY;

ADAPTIVE IMMUNITY; ANIMALS; ANTIGENS, VIRAL; DENGUE; DENGUE VACCINES; DENGUE VIRUS; HUMANS;

EID: 79953035293     PISSN: 07320582     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev-immunol-031210-101315     Document Type: Article

References (209)

1. Burke DS, Monath TP. 2001. Flaviviruses. See Ref. 208, pp. 1043-125 .
2. Fried JR, Gibbons RV, Kalayanarooj S, Thomas SJ, Srikiatkhachorn A, et al. 2010. Serotype-specific differences in the risk of dengue hemorrhagic fever: an analysis of data collected in Bangkok, Thailand from 1994 to 2006. PLoS Negl. Trop. Dis. 4:e617 .
3. Gibbons RV, Kalanarooj S, Jarman RG, Nisalak A, Vaughn DW, et al. 2007. Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences. Am. J. Trop. Med. Hyg. 77:910-13 . (Pubitemid 351837840)
4. World Health Organ. 1997. Dengue Haemorrhagic Fever: Diagnosis, Treatment, Prevention and Control. Geneva:WHO .
5. Gubler DJ, Meltzer M. 1999. Impact of dengue/dengue hemorrhagic fever on the developing world. Adv. Virus Res. 53:35-70 .
6. Suaya JA, Shepard DS, Siqueira JB, Martelli CT, Lum LC, et al. 2009. Cost of dengue cases in eight countries in the Americas and Asia: a prospective study. Am. J. Trop. Med. Hyg. 80:846-55 .
7. Gubler DJ. 1997. Dengue and dengue hemorrhagic fever: its history and resurgence as a global public health problem. See Ref. 209, pp. 1-22 .
8. Thomas SJ, Strickman D, Vaughn DW. 2003. Dengue epidemiology: virus epidemiology, ecology, and emergence. Adv. Virus Res. 61:235-89 . (Pubitemid 137639388)
9. Mackenzie JS, Gubler DJ, Petersen LR. 2004. Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat. Med. 10:S98-109 .
10. Kyle JL, Harris E. 2008. Global spread and persistence of dengue. Annu. Rev. Microbiol. 62:71-92 .
11. Ooi EE, Gubler DJ. 2009. Dengue in Southeast Asia: epidemiological characteristics and strategic challenges in disease prevention. Cad Saude Publica 25(Suppl. 1):S115-24 .
12. Wilder-Smith A, Gubler DJ. 2008. Geographic expansion of dengue: the impact of international travel. Med. Clin. North Am. 92:1377-90 .
13. Rodhain F, Rosen L. 1997. Mosquito vectors and dengue virus-vector relationships. See Ref. 209, pp. 45- 60 .
14. Effler PV, Pang L, Kitsutani P, Vorndam V, Nakata M, et al. 2005. Dengue fever, Hawaii, 2001-2002. Emerg. Infect. Dis. 11:742-49 .
15. Gubler DJ. 1998. Dengue and dengue hemorrhagic fever. Clin. Microbiol. Rev. 11:480-96 . (Pubitemid 28379096)
16. Whitehead SS, Falgout B, Hanley KA, Blaney JE Jr, Markoff L, Murphy BR. 2003. A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3 untranslated region is highly attenuated and immunogenic in monkeys. J. Virol. 77:1653-57 . (Pubitemid 36055591)
17. Blaney JE Jr, Hanson CT, Firestone CY, Hanley KA, Murphy BR, Whitehead SS. 2004. Genetically modified, live attenuated dengue virus type 3 vaccine candidates. Am. J. Trop. Med. Hyg. 71:811-21 . (Pubitemid 40075635)
18. Blaney JE Jr, Hanson CT, Hanley KA, Murphy BR, Whitehead SS. 2004. Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2. BMC Infect. Dis. 4:39 .
19. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, et al. 2000. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J. Infect. Dis. 181:2-9 . (Pubitemid 30049026)
20. Vasilakis N, Holmes EC, Fokam EB, Faye O, Diallo M, et al. 2007. Evolutionary processes among sylvatic dengue type 2 viruses. J. Virol. 81:9591-95 . (Pubitemid 47311506)
21. Vasilakis N, Tesh RB, Weaver SC. 2008. Sylvatic dengue virus type 2 activity in humans, Nigeria, 1966. Emerg. Infect. Dis. 14:502-4 . (Pubitemid 351451406)
22. Cardosa J, Ooi MH, Tio PH, Perera D, Holmes EC, et al. 2009. Dengue virus serotype 2 from a sylvatic lineage isolated from a patient with dengue hemorrhagic fever. PLoS Negl. Trop. Dis. 3:e423 .
23. Mohammed HP, Ramos MM, Rivera A, Johansson M, Munoz-Jordan JL, et al. 2010. Travel-associated dengue infections in the United States, 1996 to 2005. J. Travel Med. 17:8-14 .
24. Lanciotti RS, Gubler DJ, Trent DW. 1997. Molecular evolution and phylogeny of dengue-4 viruses. J. Gen. Virol. 78(Pt. 9):2279-84 .
25. Lanciotti RS, Lewis JG, Gubler DJ, TrentDW. 1994. Molecular evolution and epidemiology of dengue- 3 viruses. J. Gen. Virol. 75(Pt. 1):65-75 . (Pubitemid 24033981)
26. Lewis JA, Chang GJ, Lanciotti RS, Kinney RM, Mayer LW, Trent DW. 1993. Phylogenetic relationships of dengue-2 viruses. Virology 197:216-24 .
27. ChuMC, O'Rourke EJ, Trent DW. 1989. Genetic relatedness among structural protein genes of dengue 1 virus strains. J. Gen. Virol. 70(Pt. 7):1701-12 . (Pubitemid 19170207)
28. Srikiatkhachorn A, Gibbons RV, Green S, Libraty DH, Thomas SJ, et al. 2010. Dengue hemorrhagic fever: the sensitivity and specificity of the World Health Organization definition for identification of severe cases of dengue in Thailand, 1994-2005. Clin. Infect. Dis. 50:1135-43 .
29. Endy TP, Chunsuttiwat S, Nisalak A, Libraty DH, Green S, et al. 2002. Epidemiology of inapparent and symptomatic acute dengue virus infection: a prospective study of primary school children in Kamphaeng Phet, Thailand. Am. J. Epidemiol. 156:40-51 . (Pubitemid 34680622)
30. Guzman MG, Kouri G, Valdes L, Bravo J, Alvarez M, et al. 2000. Epidemiologic studies on dengue in Santiago de Cuba, 1997. Am. J. Epidemiol. 152:793-99 .
31. Rush B. 1789. An account of the bilious remitting fever, as it appeared in Philadelphia, in the summer and autumn of the year 1780. In Medical Inquiries and Observations, pp. 89-100. Philadelphia: Prichard and Hall .
32. Halstead SB, Yamarat C, Scanlon JE. 1963. TheThai hemorrhagic fever epidemic of 1962: a preliminary report. J. Med. Assoc. Thai. 46:449-62 .
33. Endy TP, Yoon IK, Mammen MP. 2010. Prospective cohort studies of dengue viral transmission and severity of disease. Curr. Top. Microbiol. Immunol. 338:1-13 .
34. Balmaseda A, Standish K, Mercado JC, Matute JC, Tellez Y, et al. 2010. Trends in patterns of dengue transmission over 4 years in a pediatric cohort study in Nicaragua. J. Infect. Dis. 201:5-14 .
35. Sabin AB. 1952. Research on dengue during World War II. Am. J. Trop. Med. Hyg. 1:30-50 .
36. Siler JF, Hall MW, Hitchens AP. 1926. Dengue: its history, epidemiology, mechanism of transmission, etiology, clinical manifestations, immunity, and prevention. Philipp. J. Sci. 29:1-304 .
37. Simmons JS, St John JH, Reynolds FHK. 1931. Experimental studies of dengue. Philipp. J. Sci. 44:1-252 .
38. Eram S, Setyabudi Y, Sadono I, SutrisnoDS, Gubler DJ, Saroso JS. 1979. Epidemic dengue hemorrhagic fever in rural Indonesia: II. Clinical studies. Am. J. Trop. Med. Hyg. 28:711-16 . (Pubitemid 9233207)
39. Halstead SB, Nimmannitya S, Margiotta MR. 1969. Dengue and Chikungunya virus infection in man in Thailand, 1962-1964: II. Observations on disease in outpatients. Am. J. Trop. Med. Hyg. 18:972-83 .
40. Palucka AK. 2000. Dengue virus and dendritic cells. Nat. Med. 6:748-49 . (Pubitemid 30469416)
41. Boonnak K, Slike BM, Burgess TH, Mason RM, Wu SJ, et al. 2008. Role of dendritic cells in antibodydependent enhancement of dengue virus infection. J. Virol. 82:3939-51 . (Pubitemid 351521231)
42. Kou Z, Quinn M, Chen H, Rodrigo WW, Rose RC, et al. 2008. Monocytes, but not T or B cells, are the principal target cells for dengue virus (DV) infection among human peripheral blood mononuclear cells. J. Med. Virol. 80:134-46 . (Pubitemid 350220099)
43. Blackley S, Kou Z, Chen H, Quinn M, Rose RC, et al. 2007. Primary human splenic macrophages, but not T or B cells, are the principal target cells for dengue virus infection in vitro. J. Virol. 81:13325-34 . (Pubitemid 350247829)
44. Jessie K, FongMY, Devi S, Lam SK, Wong KT. 2004. Localization of dengue virus in naturally infected human tissues, by immunohistochemistry and in situ hybridization. J. Infect. Dis. 189:1411-18 . (Pubitemid 38543590)
45. Lai PC, Lee SS, Kao CH, Chen YS, Huang CK, et al. 2004. Characteristics of a dengue hemorrhagic fever outbreak in 2001 in Kaohsiung. J. Microbiol. Immunol. Infect. 37:266-70 . (Pubitemid 39446664)
46. Halstead SB, Udomsakdi S, Simasathien P, Singharaj P, Sukhavachana P, Nisalak A. 1970. Observations related to pathogenesis of dengue hemorrhagic fever. I. Experience with classification of dengue viruses. Yale J. Biol. Med. 42:261-75 .
47. Halstead SB, Scanlon J, Umpaivit P, Udomsakdi S. 1969. Dengue and Chikungunya virus infection in man in Thailand, 1962-1964: IV. Epidemiologic studies in the Bangkok metropolitan area. Am. J. Trop. Med. Hyg. 18:997-1021 .
48. Innis BL. 1995. Dengue and dengue hemorrhagic fever. In Kass Handbook of Infectious Diseases: Exotic Virus Infections, ed. JS Porterfield, pp. 103-46. London: Chapman & Hall Med. .
49. Kalayanarooj S, Nimmannitya S. 2003. Clinical presentations of dengue hemorrhagic fever in infants compared to children. J. Med. Assoc. Thai. 86(Suppl. 3):S673-80 . (Pubitemid 38009759)
50. Souza LJ, Alves JG, Nogueira RM, Gicovate Neto C, Bastos DA, et al. 2004. Aminotransferase changes and acute hepatitis in patients with dengue fever: analysis of 1, 585 cases. Braz. J. Infect. Dis. 8:156-63 .
51. Kuo CH, Tai DI, Chang Chien CS, Lan CK, Chiou SS, Liaw YF. 1992. Liver biochemical tests and dengue fever. Am. J. Trop. Med. Hyg. 47:265-70 .
52. Kularatne SA, Gawarammana IB, Kumarasiri PR. 2005. Epidemiology, clinical features, laboratory investigations and early diagnosis of dengue fever in adults: a descriptive study in Sri Lanka. Southeast Asian J. Trop. Med. Public Health 36:686-92 . (Pubitemid 41316795)
53. Wright PF, Durbin AP, Whitehead SS, IkizlerMR, Henderson S, et al. 2009. Phase 1 trial of the dengue virus type 4 vaccine candidate rDEN4-30-4995 in healthy adult volunteers. Am. J. Trop. Med. Hyg. 81:834-41 .
54. McArthur JH, DurbinAP, Marron JA, Wanionek KA, Thumar B, et al. 2008. Phase I clinical evaluation of rDEN4-30-200, 201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity. Am. J. Trop. Med. Hyg. 79:678-84 .
55. Durbin AP, McArthur JH, Marron JA, Blaney JE, Thumar B, et al. 2006. rDEN2/4-30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naive adults. Hum. Vaccin. 2:255-60 .
56. Durbin AP, McArthur J, Marron JA, Blaney JE, Thumar B, et al. 2006. The live attenuated dengue serotype 1 vaccine rDEN1-30 is safe and highly immunogenic in healthy adult volunteers. Hum. Vaccin. 2:167-73 . (Pubitemid 44422483)
57. Durbin AP, Whitehead SS, McArthur J, Perreault JR, Blaney JE, et al. 2005.rDEN4 30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. J. Infect. Dis. 191:710-18 . (Pubitemid 40271058)
58. Carlos CC, Oishi K, Cinco MT, Mapua CA, Inoue S, et al. 2005. Comparison of clinical features and hematologic abnormalities between dengue fever and dengue hemorrhagic fever among children in the Philippines. Am. J. Trop. Med. Hyg. 73:435-40 . (Pubitemid 41278725)
59. Nimmannitya S. 1987. Clinical spectrum andmanagement of dengue haemorrhagic fever. Southeast Asian J. Trop. Med. Public Health 18:392-97 .
60. Murgue B, Roche C, Chungue E, Deparis X. 2000. Prospective study of the duration and magnitude of viraemia in children hospitalised during the 1996-1997 dengue-2 outbreak in French Polynesia. J. Med. Virol. 60:432-38 . (Pubitemid 30127315)
61. Pramulijo HS, Harun SR. 1991. Ultrasound findings in dengue haemorrhagic fever. Pediatr. Radiol. 21:100-2 .
62. Venkata Sai PM, Dev B, Krishnan R. 2005. Role of ultrasound in dengue fever. Br. J. Radiol. 78:416-18 . (Pubitemid 40691744)
63. Moxon C, Wills B. 2008. Management of severe dengue in Children. Adv. Exp. Med. Biol. 609:131-44 .
64. Rocha C, Silva S, Gordon A, Hammond SN, Elizondo D, et al. 2009. Improvement in hospital indicators after changes in dengue case management in Nicaragua. Am. J. Trop. Med. Hyg. 81:287-92 .
65. Subramanian V, Shenoy S, Joseph AJ. 2005. Dengue hemorrhagic fever and fulminant hepatic failure. Dig. Dis. Sci. 50:1146-47 . (Pubitemid 40864025)
66. Patey O, Ollivaud L, Breuil J, Lafaix C. 1993. Unusual neurologic manifestations occurring during dengue fever infection. Am. J. Trop. Med. Hyg. 48:793-802 . (Pubitemid 23238460)
67. Nimmannitya S, Thisyakorn U, Hemsrichart V. 1987. Dengue haemorrhagic fever with unusual manifestations. Southeast Asian J. Trop. Med. Public Health 18:398-406 .
68. Kho LK, Sumarmo, Wulur H, Jahja E, Gubler DJ. 1981. Dengue hemorrhagic fever accompanied by encephalopathy in Jakarta. Southeast Asian J. Trop. Med. Public Health 12:83-86 . (Pubitemid 11036249)
69. Wichmann O, Hongsiriwon S, Bowonwatanuwong C, Chotivanich K, Sukthana Y, Pukrittayakamee S. 2004. Risk factors and clinical features associated with severe dengue infection in adults and children during the 2001 epidemic in Chonburi, Thailand. Trop. Med. Int. Health 9:1022-29 . (Pubitemid 39279005)
70. Rothman AL. 2009. T lymphocyte responses to heterologous secondary dengue virus infections. Ann. N. Y. Acad. Sci. 1171(Suppl. 1):E36-41 .
71. Rothman AL. 2004. Dengue: defining protective versus pathologic immunity. J. Clin. Investig. 113:946-51 . (Pubitemid 38544112)
72. Martina BE, Koraka P, Osterhaus AD. 2009. Dengue virus pathogenesis: an integrated view. Clin. Microbiol. Rev. 22:564-81 .
73. Halstead SB, Suaya JA, Shepard DS. 2007. The burden of dengue infection. Lancet 369:1410-11 . (Pubitemid 46635764)
74. Coffey LL, Mertens E, Brehin AC, Fernandez-Garcia MD, Amara A, et al. 2009. Human genetic determinants of dengue virus susceptibility. Microbes Infect. 11:143-56 .
75. Stephens HA. 2010. HLA and other gene associations with dengue disease severity. Curr. Top. Microbiol. Immunol. 338:99-114 .
76. Silva LK, Blanton RE, Parrado AR, Melo PS, Morato VG, et al. 2010. Dengue hemorrhagic fever is associated with polymorphisms in JAK1. Eur. J. Hum. Genet. 18(11):1221-27 .
77. Lindenbach BD, Rice CM. 2001. Flaviviridae: the viruses and their replication. See Ref. 208, pp. 1043- 125 .
78. Clyde K, Harris E. 2006. RNA secondary structure in the coding region of dengue virus type 2 directs translation start codon selection and is required for viral replication. J. Virol. 80:2170-82 . (Pubitemid 43271524)
79. Modis Y, Ogata S, Clements D, Harrison SC. 2005. Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein. J. Virol. 79:1223-31 . (Pubitemid 40053904)
80. Mukhopadhyay S, Kuhn RJ, Rossmann MG. 2005. A structural perspective of the flavivirus life cycle. Nat. Rev. Microbiol. 3:13-22 . (Pubitemid 40028466)
81. Pokidysheva E, Zhang Y, Battisti AJ, Bator-KellyCM, Chipman PR, et al. 2006. Cryo-EM reconstruction of dengue virus in complex with the carbohydrate recognition domain of DC-SIGN. Cell 124:485-93 . (Pubitemid 43199435)
82. Westaway EG, Blok J. 1997. Taxonomy and evolutionary relationships of flaviviruses. See Ref. 209, pp. 147-74 .
83. Zanotto PM, Gould EA, Gao GF, Harvey PH, Holmes EC. 1996. Population dynamics of flaviviruses revealed by molecular phylogenies. Proc. Natl Acad. Sci. USA 93:548-53 . (Pubitemid 26041125)
84. Allison SL, Schalich J, Stiasny K, Mandl CW, Heinz FX. 2001. Mutational evidence for an internal fusion peptide in flavivirus envelope protein E. J. Virol. 75:4268-75 . (Pubitemid 32410139)
85. Modis Y, Ogata S, Clements D, Harrison SC. 2004. Structure of the dengue virus envelope protein after membrane fusion. Nature 427:313-19 . (Pubitemid 38133652)
86. Rey FA, Heinz FX, Mandl C, Kunz C, Harrison SC. 1995. The envelope glycoprotein from tick-borne encephalitis virus at 2 angstrom resolution. Nature 375:291-98 .
87. WahalaWM, Kraus AA, HaymoreLB, Accavitti-LoperMA, de Silva AM. 2009. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology 392:103-13 .
88. Gollins SW, Porterfield JS. 1986. A new mechanism for the neutralization of enveloped viruses by antiviral antibody. Nature 321:244-46 . (Pubitemid 16016417)
89. Nybakken GE, Oliphant T, Johnson S, Burke S, Diamond MS, Fremont DH. 2005. Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature 437:764-69 . (Pubitemid 41486548)
90. Throsby M, Geuijen C, Goudsmit J, Bakker AQ, Korimbocus J, et al. 2006. Isolation and characterization of humanmonoclonal antibodies from individuals infected with West Nile Virus. J. Virol. 80(14):6982-92 . (Pubitemid 44025197)
91. Innis BL. 1997. Antibody responses to dengue virus infection. See Ref. 209, pp. 221-43 .
92. Koraka P, Suharti C, Setiati TE, Mairuhu AT, Van Gorp E, et al. 2001. Kinetics of dengue virusspecific serum immunoglobulin classes and subclasses correlate with clinical outcome of infection. J. Clin. Microbiol. 39:4332-38 . (Pubitemid 33117119)
93. Crill WD, Hughes HR, Delorey MJ, Chang GJ. 2009. Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens. PLoS ONE 4:e4991 .
94. Kyle JL, Balsitis SJ, Zhang L, Beatty PR, Harris E. 2008. Antibodies play a greater role than immune cells in heterologous protection against secondary dengue virus infection in a mouse model. Virology 380:296-303 .
95. Endy TP, Nisalak A, Chunsuttitwat S, Vaughn DW, Green S, et al. 2004. Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J. Infect. Dis. 189:990-1000 . (Pubitemid 38373090)
96. Halstead SB. 2009. Antibodies determine virulence in dengue. Ann. N. Y. Acad. Sci. 1171(Suppl. 1):E48- 56 .
97. Churdboonchart V, Bhamarapravati N, Peampramprecha S, Sirinavin S. 1991. Antibodies against dengue viral proteins in primary and secondary dengue hemorrhagic fever. Am. J. Trop. Med. Hyg. 44:481-93 .
98. Valdes K, Alvarez M, Pupo M, Vazquez S, Rodriguez R, GuzmanMG. 2000. Human dengue antibodies against structural and nonstructural proteins. Clin. Diagn. Lab. Immunol. 7:856-57 .
99. Lai CY, Tsai WY, Lin SR, Kao CL, Hu HP, et al. 2008. Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. J. Virol. 82:6631-43 .
100. Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L, et al. 2010. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 8(3):271-83 .
101. Sangkawibha N, Rojanasuphot S, Ahandrik S, Viriyapongse S, Jatanasen S, et al. 1984. Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak. Am. J. Epidemiol. 120:653-69 . (Pubitemid 15210730)
102. Halstead SB, Lan NT, Myint TT, Shwe TN, Nisalak A, et al. 2002. Dengue hemorrhagic fever in infants: research opportunities ignored. Emerg. Infect. Dis. 8:1474-79 . (Pubitemid 36008787)
103. Kliks SC, Nimmannitya S, Nisalak A, Burke DS. 1988. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am. J. Trop. Med. Hyg. 38:411-19 . (Pubitemid 18086128)
104. Pengsaa K, Luxemburger C, Sabchareon A, Limkittikul K, Yoksan S, et al. 2006. Dengue virus infections in the first 2 years of life and the kinetics of transplacentally transferred dengue neutralizing antibodies in Thai children. J. Infect. Dis. 194:1570-76 . (Pubitemid 44851899)
105. Chau TN, HieuNT, Anders KL, Wolbers M, Lien le B, et al. 2009. Dengue virus infections and maternal antibody decay in a prospective birth cohort study of Vietnamese infants. J. Infect. Dis. 200:1893-900 .
106. Libraty DH, Acosta LP, Tallo V, Segubre-Mercado E, Bautista A, et al. 2009. A prospective nested case-control study of dengue in infants: rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model. PLoS Med. 6:e1000171 .
107. Bellanti JA, Bourke RTA, Rosenzweig EC, Eylar OR. 1966. Report of dengue vaccine trial in the Caribbean, 1963: a collaborative study. Bull. World Health Organ. 35:93 .
108. Blaney JE Jr, Matro JM, Murphy BR, Whitehead SS. 2005. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys. J. Virol. 79:5516-28 . (Pubitemid 40548220)
109. Sun W, Edelman R, Kanesa-Thasan N, Eckels KH, Putnak JR, et al. 2003. Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates. Am. J. Trop. Med. Hyg. 69:24-31 .
110. Edelman R, Wasserman SS, Bodison SA, Putnak RJ, Eckels KH, et al. 2003. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am. J. Trop. Med. Hyg. 69:48-60 .
111. Simmons M, Burgess T, Lynch J, Putnak R. 2010. Protection against dengue virus by nonreplicating and live attenuated vaccines used together in a prime boost vaccination strategy. Virology 396:280-88 .
112. Pierson TC, Diamond MS. 2008. Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection. Expert Rev. Mol. Med. 10:e12 .
113. Rodrigo WW, Block OK, Lane C, Sukupolvi-Petty S, Goncalvez AP, et al. 2009. Dengue virus neutralization is modulated by IgG antibody subclass and Fcγreceptor subtype. Virology 394:175-82 .
114. Pierson TC, Fremont DH, Kuhn RJ, DiamondMS. 2008. Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development. Cell Host Microbe 4:229-38 .
115. Mehlhop E, Nelson S, Jost CA, Gorlatov S, Johnson S, et al. 2009. Complement protein C1q reduces the stoichiometric threshold for antibody-mediated neutralization ofWest Nile virus. Cell Host Microbe 6:381-91 .
116. Zhang Y, Kaufmann B, Chipman PR, Kuhn RJ, Rossmann MG. 2007. Structure of immature West Nile virus. J. Virol. 81:6141-45 . (Pubitemid 46847052)
117. Nelson S, Jost CA, Xu Q, Ess J, Martin JE, et al. 2008. Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization. PLoS Pathog. 4:e1000060 .
118. Goncalvez AP, Purcell RH, Lai CJ. 2010. Progress in passive immunotherapy. In Frontiers in Dengue Virus Research, ed. KA Hanley, SCWeaver, pp. 265-97. Norfolk: Caister Acad. Press .
119. Thullier P, Lafaye P, Megret F, Deubel V, Jouan A, Mazie JC. 1999. A recombinant Fab neutralizes dengue virus in vitro. J. Biotechnol. 69:183-90 . (Pubitemid 29206499)
120. Kaufman BM, Summers PL, Dubois DR, CohenWH, Gentry MK, et al. 1989. Monoclonal antibodies for dengue virus prM glycoprotein protect mice against lethal dengue infection. Am. J. Trop. Med. Hyg. 41:576-80 . (Pubitemid 20000630)
121. Kaufman BM, Summers PL, Dubois DR, Eckels KH. 1987. Monoclonal antibodies against dengue 2 virus E-glycoprotein protect mice against lethal dengue infection. Am. J. Trop. Med. Hyg. 36:427-34 . (Pubitemid 17057550)
122. Tan CH, Yap EH, Singh M, Deubel V, Chan YC. 1990. Passive protection studies in mice with monoclonal antibodies directed against the nonstructural protein NS3 of dengue 1 virus. J. Gen. Virol. 71:745-49 . (Pubitemid 20111924)
123. Henchal EA, Henchal LS, Schlesinger JJ. 1988. Synergistic interactions of anti-NS1 monoclonal antibodies protect passively immunized mice from lethal challenge with dengue 2 virus. J. Gen. Virol. 69:2101-7 .
124. Mathew A, Rothman AL. 2008. Understanding the contribution of cellular immunity to dengue disease pathogenesis. Immunol. Rev. 225:300-13 .
125. Myint KS, Endy TP, Mongkolsirichaikul D, Manomuth C, Kalayanarooj S, et al. 2006. Cellular immune activation in childrenwith acute dengue virus infections ismodulated by apoptosis. J. Infect. Dis. 194:600-7 . (Pubitemid 44297845)
126. Mongkolsapaya J, Duangchinda T, Dejnirattisai W, Vasanawathana S, Avirutnan P, et al. 2006. T cell responses in dengue hemorrhagic fever: Are cross-reactive T cells suboptimal? J. Immunol. 176:3821-29 . (Pubitemid 43364031)
127. Mongkolsapaya J, Dejnirattisai W, Xu XN, Vasanawathana S, Tangthawornchaikul N, et al. 2003. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat. Med. 9:921-27 . (Pubitemid 36889936)
128. Mangada MM, Endy TP, Nisalak A, Chunsuttiwat S, Vaughn DW, et al. 2002. Dengue-specific T cell responses in peripheral blood mononuclear cells obtained prior to secondary dengue virus infections in Thai schoolchildren. J. Infect. Dis. 185:1697-703 . (Pubitemid 34615461)
129. Rothman AL. 2009. T lymphocyte responses to heterologous secondary dengue virus infections. Ann. N. Y. Acad. Sci. 1171(Suppl. 1):E36-41 .
130. Yauch LE, Zellweger RM, Kotturi MF, Qutubuddin A, Sidney J, et al. 2009. A protective role for dengue virus-specific CD8+ T cells. J. Immunol. 182:4865-73 .
131. Gil L, Lopez C, Blanco A, Lazo L, Martin J, et al. 2009. The cellular immune response plays an important role in protecting against dengue virus in the mouse encephalitis model. Viral. Immunol. 22:23-30 .
132. Calvert AE, Huang CY, Kinney RM, Roehrig JT. 2006. Non-structural proteins of dengue 2 virus offer limited protection to interferon-deficient mice after dengue 2 virus challenge. J. Gen. Virol. 87:339-46 . (Pubitemid 43169260)
133. Guzman MG, Kouri G, Martinez E, Bravo J, Riveron R, et al. 1987. Clinical and serologic study of Cuban children with dengue hemorrhagic fever/dengue shock syndrome (DHF/DSS). Bull. Pan Am. Health Organ. 21:270-79 .
134. Halstead SB, Nimmannitya S, Cohen SN. 1970. Observations related to pathogenesis of dengue hemorrhagic fever. IV. Relation of disease severity to antibody response and virus recovered. Yale J. Biol. Med. 42:311-28 .
135. BurkeDS, Nisalak A, Johnson DE, Scott RM. 1988. A prospective study of dengue infections in Bangkok. Am. J. Trop. Med. Hyg. 38:172-80 . (Pubitemid 18036130)
136. Halstead SB, Lan NT, Myint TT, Shwe TN, Nisalak A, et al. 2002. Dengue hemorrhagic fever in infants: research opportunities ignored. Emerg. Infect. Dis. 8(12):1474-79 . (Pubitemid 36008787)
137. Libraty DH, Acosta LP, Tallo V, Segubre-Mercado E, Bautista A, et al. 2009. A prospective nested case-control study of Dengue in infants: rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model. PLoS Med. 6(10):e1000171 .
138. Goncalvez AP, Engle RE, St Claire M, Purcell RH, Lai CJ. 2007. Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc. Natl Acad. Sci. USA 104:9422-27 . (Pubitemid 47185795)
139. Halstead SB. 1979. In vivo enhancement of dengue virus infection in Rhesus monkeys by passively transferred antibody. J. Infect. Dis. 140:527-33 . (Pubitemid 10172725)
140. Balsitis SJ, Williams KL, Lachica R, Flores D, Kyle JL, et al. 2010. Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog. 6:e1000790 .
141. Zellweger RM, Prestwood TR, Shresta S. 2010. Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease. Cell Host Microbe 7:128-39 .
142. Halstead SB. 2009. Antibodies determine virulence in dengue. Ann. N. Y. Acad. Sci. 1171(Suppl. 1):E48- 56 .
143. Rodenhuis-Zybert IA, Wilschut J, Smit JM. 2010. Dengue virus life cycle: viral and host factors modulating infectivity. Cell. Mol. Life Sci. 67:2773-86 .
144. Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, et al. 2010. Cross-reacting antibodies enhance dengue virus infection in humans. Science 328:745-48 .
145. Kurane I, Ennis FA. 1997. Immunopathogenesis of dengue virus infections. See Ref. 209, pp. 273-90 .
146. Rothman AL. 2010. Cellular immunology of sequential dengue virus infection and its role in disease pathogenesis. Curr. Top. Microbiol. Immunol. 338:83-98 .
147. Nguyen TH, Lei HY, Nguyen TL, Lin YS, Huang KJ, et al. 2004. Dengue hemorrhagic fever in infants: a study of clinical and cytokine profiles. J. Infect. Dis. 189:221-32 .
148. Green S, Rothman A. 2006. Immunopathological mechanisms in dengue and dengue hemorrhagic fever. Curr. Opin. Infect. Dis. 19:429-36 . (Pubitemid 44338101)
149. Kliks SC, Nisalak A, Brandt WE, Wahl L, Burke DS. 1989. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am. J. Trop. Med. Hyg. 40:444-51 . (Pubitemid 19117544)
150. Stephenson JR. 2005. Understanding dengue pathogenesis: implications for vaccine design. Bull. World Health Organ. 83:308-14 . (Pubitemid 40529628)
151. Avirutnan P, Punyadee N, Noisakran S, Komoltri C, Thiemmeca S, et al. 2006. Vascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein NS1 and complement. J. Infect. Dis. 193:1078-88 .
152. RodrigoWW, Jin X, Blackley SD, Rose RC, Schlesinger JJ. 2006. Differential enhancement of dengue virus immune complex infectivity mediated by signaling-competent and signaling-incompetent human FcγRIA (CD64) or FcγRIIA (CD32). J. Virol. 80:10128-38 . (Pubitemid 44522606)
153. MoiML, Lim CK, Takasaki T, Kurane I. 2010. Involvement of the Fcγreceptor IIA cytoplasmic domain in antibody-dependent enhancement of dengue virus infection. J. Gen. Virol. 91:103-11 .
154. Huang YH, Chang BI, Lei HY, Liu HS, Liu CC, et al. 1997. Antibodies against dengue virus E protein peptide bind to human plasminogen and inhibit plasmin activity. Clin. Exp. Immunol. 110:35-40 . (Pubitemid 27428512)
155. Lin CF, WanSW, ChengHJ, LeiHY, LinYS. 2006. Autoimmune pathogenesis in dengue virus infection. Viral. Immunol. 19:127-32 .
156. Markoff LJ, Innis BL, Houghten R, Henchal LS. 1991. Development of cross-reactive antibodies to plasminogen during the immune response to dengue virus infection. J. Infect. Dis. 164:294-301 .
157. Chungue E, Poli L, Roche C, Gestas P, Glaziou P, Markoff LJ. 1994. Correlation between detection of plasminogen cross-reactive antibodies and hemorrhage in dengue virus infection. J. Infect. Dis. 170:1304-7 . (Pubitemid 24328643)
158. Shepard DS, Suaya JA, Halstead SB, NathanMB, Gubler DJ, et al. 2004. Cost-effectiveness of a pediatric dengue vaccine. Vaccine 22:1275-80 . (Pubitemid 38296672)
159. Swaminathan S, Batra G, Khanna N. 2010. Dengue vaccines: state of the art. Expert Opin. Ther. Pat. 20:819-35 .
160. Putnak R, Barvir DA, Burrous JM, Dubois DR, D'Andrea VM, et al. 1996. Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys. J. Infect. Dis. 174:1176-84 . (Pubitemid 26393894)
161. Putnak R, Cassidy K, Conforti N, Lee R, Sollazzo D, et al. 1996. Immunogenic and protective response in mice immunized with a purified, inactivated, Dengue-2 virus vaccine prototype made in fetal rhesus lung cells. Am. J. Trop. Med. Hyg. 55:504-10 . (Pubitemid 26392713)
162. Putnak R, Coller BA, Voss G, Vaughn DW, Clements D, et al. 2005. An
163. Wang PG, Kudelko M, Lo J, Siu LY, Kwok KT, et al. 2009. Efficient assembly and secretion of recombinant subviral particles of the four dengue serotypes using native prM and E proteins. PLoS ONE 4:e8325 .
164. Konishi E, Fujii A. 2002. Dengue type 2 virus subviral extracellular particles produced by a stably transfected mammalian cell line and their evaluation for a subunit vaccine. Vaccine 20:1058-67 . (Pubitemid 34135941)
165. Liu W, Jiang H, Zhou J, Yang X, Tang Y, et al. 2010. Recombinant dengue virus-like particles from Pichia pastoris: efficient production and immunological properties. Virus Genes 40:53-59 .
166. Raviprakash K, Wang D, Ewing D, Holman DH, Block K, et al. 2008. A tetravalent dengue vaccine based on a complex adenovirus vector provides significant protection in rhesus monkeys against all four serotypes of dengue virus. J. Virol. 82:6927-34 . (Pubitemid 351977713)
167. Fonseca BAL, Pincus S, Shope RE, Paoletti E, Mason PW. 1994. Recombinant vaccinia viruses coexpressing dengue-1 glycoproteins prM and E induce neutralizing antibodies in mice. Vaccine 12:279-85 . (Pubitemid 24062530)
168. White LJ, Parsons MM, Whitmore AC, Williams BM, de Silva A, Johnston RE. 2007. An immunogenic and protective alphavirus replicon particle-based dengue vaccine overcomes maternal antibody interference in weanling mice. J. Virol. 81:10329-39 . (Pubitemid 47463308)
169. De Paula SO, Lima DM, deOliveira Franca RF, Gomes-Ruiz AC, da Fonseca BA. 2008. ADNA vaccine candidate expressing dengue-3 virus prM and E proteins elicits neutralizing antibodies and protectsmice against lethal challenge. Arch. Virol. 153:2215-23 .
170. Konishi E, Kosugi S, Imoto J. 2006. Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice. Vaccine 24:2200-7 . (Pubitemid 43255164)
171. Blair PJ, Kochel TJ, Raviprakash K, Guevara C, Salazar M, et al. 2006. Evaluation of immunity and protective efficacy of a dengue-3 premembrane and envelopeDNAvaccine in Aotus nancymae monkeys. Vaccine 24:1427-32 . (Pubitemid 43222054)
172. Raviprakash K, Apt D, Brinkman A, Skinner C, Yang S, et al. 2006. A chimeric tetravalent dengue DNA vaccine elicits neutralizing antibody to all four virus serotypes in rhesus macaques. Virology 353:166-73 . (Pubitemid 44291778)
173. Raviprakash K, Kochel TJ, Ewing D, Simmons M, Phillips I, et al. 2000. Immunogenicity of dengue virus type 1 DNA vaccines expressing truncated and full length envelope protein. Vaccine 18:2426-34 . (Pubitemid 30156814)
174. Raviprakash K, Ewing D, Simmons M, Porter KR, Jones TR, et al. 2003. Needle-free biojector injection of a dengue virus type 1DNAvaccine with human immunostimulatory sequences and the GM-CSF gene increases immunogenicity and protection from virus challenge in Aotus monkeys. Virology 315:345-52 . (Pubitemid 37324624)
175. Chen L, Ewing D, Subramanian H, Block K, Rayner J, et al. 2007. A heterologous DNA prime- Venezuelan equine encephalitis virus replicon particle boost dengue vaccine regimen affords complete protection from virus challenge in cynomolgus macaques. J. Virol. 81:11634-39 . (Pubitemid 47623795)
176. Jaiswal S, Khanna N, Swaminathan S. 2003. Replication-defective adenoviral vaccine vector for the induction of immune responses to dengue virus type 2. J. Virol. 77:12907-13 . (Pubitemid 37430686)
177. Men R, Wyatt L, Tokimatsu I, Arakaki S, Shameem G, et al. 2000. Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge. Vaccine 18:3113-22 . (Pubitemid 30345693)
178. Guzman MG, Rodriguez R, Hermida L, Alvarez M, Lazo L, et al. 2003. Induction of neutralizing antibodies and partial protection from viral challenge in Macaca fascicularis immunized with recombinant dengue 4 virus envelope glycoprotein expressed in Pichia pastoris. Am. J. Trop. Med. Hyg. 69:129-34 .
179. Kelly EP, Greene JJ, King AD, Innis BL. 2000. Purified dengue 2 virus envelope glycoprotein aggregates produced by baculovirus are immunogenic in mice. Vaccine 18:2549-59 . (Pubitemid 30207040)
180. Clements DE, Coller BA, Lieberman MM, Ogata S, Wang G, et al. 2010. Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys. Vaccine 28:2705-15 .
181. Staropoli I, Frenkiel MP, Megret F, Deubel V. 1997. Affinity-purified dengue-2 virus envelope glycoprotein induces neutralizing antibodies and protective immunity in mice. Vaccine 15:1946-54 . (Pubitemid 27504692)
182. Chung KM, Nybakken GE, Thompson BS, Engle MJ, Marri A, et al. 2006. Antibodies against West Nile Virus nonstructural protein NS1 prevent lethal infection through Fcγ receptor-dependent and -independent mechanisms. J. Virol. 80:1340-51 . (Pubitemid 43134091)
183. Timofeev AV, Ozherelkov SV, Pronin AV, Deeva AV, Karganova GG, et al. 1998. Immunological basis for protection in a murine model of tick-borne encephalitis by a recombinant adenovirus carrying the gene encoding the NS1 nonstructural protein. J. Gen. Virol. 79:689-95 . (Pubitemid 28161941)
184. Wu SF, Liao CL, Lin YL, Yeh CT, Chen LK, et al. 2003. Evaluation of protective efficacy and immune mechanisms of using a nonstructural protein NS1 inDNAvaccine against dengue 2 virus in mice. Vaccine 21:3919-29 .
185. Timofeev AV, Butenko VM, Stephenson JR. 2004. Genetic vaccination of mice with plasmids encoding theNS1 non-structural protein from tick-borne encephalitis virus and dengue 2 virus. Virus Genes 28:85-97 . (Pubitemid 38161272)
186. Costa SM, Freire MS, Alves AM. 2006.DNAvaccine against the nonstructural 1 protein (NS1) of dengue 2 virus. Vaccine 24:4562-64 . (Pubitemid 44218840)
187. Falgout B, Bray M, Schlesinger JJ, Lai CJ. 1990. Immunization of mice with recombinant vaccinia virus expressing authentic dengue virus nonstructural protein NS1 protects against lethal dengue virus encephalitis. J. Virol. 64:4356-63 . (Pubitemid 20279846)
188. Guirakhoo F, Arroyo J, Pugachev KV, Miller C, Zhang ZX, et al. 2001. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J. Virol. 75:7290-304 . (Pubitemid 32737987)
189. Guirakhoo F, Kitchener S, Morrison D, Forrat R, McCarthy K, et al. 2006. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever preimmunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum. Vaccin. 2:60-67 . (Pubitemid 43927159)
190. Monath TP, Kanesa-Thasan N, Guirakhoo F, Pugachev K, Almond J, et al. 2005. Recombination and flavivirus vaccines: a commentary. Vaccine 23:2956-58 . (Pubitemid 40462433)
191. Murphy BR, Blaney JE Jr, Whitehead SS. 2004. Arguments for live flavivirus vaccines. Lancet 364:499-500 .
192. Pletnev AG, Swayne DE, Speicher J, Rumyantsev AA, Murphy BR. 2006. Chimeric West Nile/dengue virus vaccine candidate: preclinical evaluation inmice, geese and monkeys for safety and immunogenicity. Vaccine 24:6392-404 . (Pubitemid 44331996)
193. Whitehead SS, Hanley KA, Blaney JE Jr, Gilmore LE, Elkins WR, Murphy BR. 2003. Substitution of the structural genes of dengue virus type 4 with those of type 2 results in chimeric vaccine candidates which are attenuated for mosquitoes, mice, and rhesus monkeys. Vaccine 21:4307-16 . (Pubitemid 37138698)
194. Guirakhoo F, Pugachev K, Zhang Z, Myers G, Levenbook I, et al. 2004. Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J. Virol. 78:4761-75 . (Pubitemid 38501097)
195. Morrison D, Legg TJ, Billings CW, Forrat R, Yoksan S, Lang J. 2010. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J. Infect. Dis. 201:370-77 .
196. Poo J, Galan F, Forrat R, Zambrano B, Lang J, Dayan GH. 2010. Live-attenuated tetravalent dengue vaccine in dengue-nä?ve children, adolescents, and adults in Mexico City: randomized controlled Phase 1 trial of safety and immunogenicity. Pediatr. Infect. Dis. J. In press .
197. Lang J. 2009. Recent progress on Sanofi Pasteur's dengue vaccine candidate. J. Clin. Virol. 46(Suppl. 2):S20-24 .
198. Higgs S, VanlandinghamDL, Klingler KA, McElroy KL, McGee CE, et al. 2006. Growth characteristics of ChimeriVax-Den vaccine viruses in Aedes aegypti and Aedes albopictus from Thailand. Am. J. Trop.Med. Hyg. 75:986-93 . (Pubitemid 351627554)
199. Men R, Bray M, Clark D, Chanock RM, Lai CJ. 1996. Dengue type 4 virusmutants containing deletions in the 3 noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys. J. Virol. 70:3930-37 .
200. Durbin AP, Karron RA, Sun W, Vaughn DW, Reynolds MJ, et al. 2001. Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3-untranslated region. Am. J. Trop. Med. Hyg. 65:405-13 . (Pubitemid 33134570)
201. Troyer JM, Hanley KA, Whitehead SS, Strickman D, Karron RA, et al. 2001. A live attenuated recombinant dengue-4 virus vaccine candidate with restricted capacity for dissemination in mosquitoes and lack of transmission from vaccinees to mosquitoes. Am. J. Trop. Med. Hyg. 65:414-19 . (Pubitemid 33134571)
202. McArthur JH, Durbin AP, Marron JA, Wanionek KA, Thumar B, et al. 2008. Phase I clinical evaluation of rDEN4 30-200, 201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity. Am. J. Trop. Med. Hyg. 79:678-84 .
203. Deen JL, Harris E, Wills B, Balmaseda A, Hammond SN, et al. 2006. TheWHO dengue classification and case definitions: time for a reassessment. Lancet 368:170-73 . (Pubitemid 43994174)
204. Phuong CX, Nhan NT, Wills B, Kneen R, Ha NTT, et al. 2002. Evaluation of the World Health Organization standard tourniquet test and amodified tourniquet test in the diagnosis of dengue infection in Vietnam. Trop. Med. Int. Health 7:125-32 . (Pubitemid 34146789)
205. Balmaseda A, Hammond SN, Perez MA, Cuadra R, Solano S, et al. 2005. Assessment of the World Health Organization scheme for classification of dengue severity in Nicaragua. Am. J. Trop. Med. Hyg. 73:1059-62 . (Pubitemid 43038254)
206. Kuhn RJ, Zhang W, Rossmann MG, Pletnev SV, Corver J, et al. 2002. Structure of dengue virus. Implications for flavivirus organization, maturation, and fusion. Cell 108:717-25 . (Pubitemid 34241430)
207. Blaney JE Jr, Sathe NS, Goddard L, Hanson CT, Romero TA, et al. 2008. Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3 untranslated region (3-UTR) or by exchange of the DENV-3 3-UTR with that of DENV-4. Vaccine 26:817-28 .
208. Knipe DM, Mowley PM, eds. 2001. Fields Virology. Philadelphia: Lippincott, Williams, Wilkins .
209. Gubler DJ, Kuno G, eds. 1997. Dengue and Dengue Hemorrhagic Fever. New York: CAB Int.